Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can telemedicine bring IV antibiotics home?

NCT ID NCT04898452

Disease control Sponsor: Helse Møre og Romsdal HF Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests a new model where patients with infections receive intravenous antibiotics at home instead of staying in the hospital. Nurses from a municipal response team visit the patient, while hospital doctors oversee the treatment remotely using telemedicine and welfare technology. The study aims to see if this approach is safe, reduces rehospitalizations, and satisfies patients and healthcare staff. If it works, it could change how IV treatments are delivered and be applied to other conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A new care model using telemedicine and welfare technology to deliver intravenous antibiotics at home, with hospital physicians overseeing care remotely.
What this could lead to
If successful, this could offer a safe alternative to hospital stays for IV antibiotics, improving patient comfort and freeing hospital resources.
What could go wrong
The trial is small and early, so results may not apply broadly. Risks include complications from home-based IV therapy, such as infection or adverse reactions, which may require rehospitalization.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

19 people

The number who actually took part.

Started

Jul 2020

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients participate in both study part 1 (qualitative) and study part 2 (quantitative). Health professionals and next to kins participate in study part 1 (qualitative).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Main or bi-diagnosis during stay: A692 Borreliosis G00 - G009 Central nervous system inflammatory disorders I33 Endocarditis J86 Empyema D46.3 Spondylodiscitis M86 Osteomyelitis T84 Prosthesis / osteosynthesis infections M00.0-M00.9 Pyogen / septic arthritis J40-J47 Chronic diseases of the lower respiratory tract * Competent to give consent * The infection can not be treated with oral antibiotics in monotherapy * Selected IV antibiotics must be suitable for administration via selected pumps * The patient's condition is stable and does not require frequent observation by health care professionals * The patient is motivated and willing to participate in intravenous treatment in home hospitals * Must, after training, demonstrate mastery of practical procedures related to pump handling and any other procedures described in the patient's treatment plan * The home must be suitable for intravenous antibiotic treatment; access to refrigerators, hygienic conditions, social conditions * The patient must have a mobile phone and be able to handle the system for fast and secure communication with the Regional Response Center (RRO) Exclusion criteria: * consent not given

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Empyema are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial arthritis empyema endocarditis Infections infectious disease Lyme disease osteomyelitis prosthesis-related infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infection

Contacts and locations

Locations

  • Helse Møre og Romsdal HF, Kristiansund sjukehus, Medisinsk Avdeling

    Kristiansund, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.